Wird geladen...
Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID‐19 pandemic
Tofacitinib is a Janus Kinase 3 inhibitor that is used in the treatment of alopecia areata. We recommended our alopecia areata patients to discontinue their tofacitinib treatment during the COVID‐19 pandemic for an average of 80 days. We aimed to evaluate the drug use and the SARS‐CoV‐2 infection st...
Gespeichert in:
| Veröffentlicht in: | Dermatol Ther |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley & Sons, Inc.
2021
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7883269/ https://ncbi.nlm.nih.gov/pubmed/33405372 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dth.14746 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|